In This Article:
In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability in response to evolving market dynamics.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.44% | 29.79% | ★★★★★★ |
| TG Therapeutics | 26.18% | 37.61% | ★★★★★★ |
| Alkami Technology | 20.46% | 85.16% | ★★★★★★ |
| Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
| Clene | 60.86% | 63.07% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.76% | 58.56% | ★★★★★★ |
| AVITA Medical | 27.91% | 55.77% | ★★★★★★ |
| TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
| Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
| Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Chimerix
Simply Wall St Growth Rating: ★★★★★☆
Overview: Chimerix, Inc. is a biopharmaceutical company focused on developing medicines to enhance and prolong the lives of patients with life-threatening diseases, with a market cap of approximately $797.33 million.
Operations: Chimerix generates revenue primarily from its pharmaceuticals segment, which contributed $0.21 million.
Chimerix, despite its modest revenue of $212K, is on a trajectory with a forecasted annual revenue growth rate of 52.8%, significantly outpacing the US market's 8.3%. The company's recent earnings report revealed a jump in quarterly revenue to $0.057 million from $0.004 million year-over-year, although it still posted a substantial net loss of $22.95 million. Notably, Chimerix is poised for transformation through an impending acquisition by Jazz Pharmaceuticals for approximately $930 million, promising substantial cash per share to stakeholders and potentially stabilizing its financial footing as it moves towards profitability projected within three years.
-
Navigate through the intricacies of Chimerix with our comprehensive health report here.
-
Review our historical performance report to gain insights into Chimerix's's past performance.
Apellis Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutic compounds for diseases with high unmet needs, with a market cap of approximately $3.05 billion.
Operations: Apellis Pharmaceuticals focuses on developing and commercializing proprietary therapeutics, generating approximately $781.37 million in revenue from these activities.